Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moleculin Biotech ( (MBRX) ) has provided an update.
On May 8, 2026, Moleculin Biotech announced it had secured a new Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin, extending protection through June 25, 2040. The invention, jointly owned with The University of Texas System, adds to a portfolio of patents already granted across the United States, Europe, Asia and other regions, bolstering protection around the company’s lead oncology asset.
The patent strengthens Moleculin’s global exclusivity strategy for Annamycin by securing rights in Hong Kong, a key gateway to broader Asian markets, at a time when the oncology sector is seeking better treatment options. This additional layer of intellectual property protection is positioned to support the company’s upcoming Phase 3 data readout for Annamycin and underpins Moleculin’s long-term plans for commercialization and value creation across major cancer markets.
The most recent analyst rating on (MBRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn implying financing dependence). Technicals are neutral-to-weak with longer-term downtrend indications, while valuation is hard to support due to negative earnings. Corporate events are a relative positive driven by clinical/patent progress, but dilution risk remains.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin (naxtarubicin), is an anthracycline designed to avoid multidrug resistance and cardiotoxicity and is being developed for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company is conducting the pivotal MIRACLE Phase 3 trial of Annamycin in combination with cytarabine for relapsed or refractory AML, following positive Phase 1B/2 data and regulatory input. Moleculin is also advancing WP1066, an immune/transcription modulator for various cancers, and a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses and certain cancer indications.
Average Trading Volume: 158,687
Technical Sentiment Signal: Sell
Current Market Cap: $13.29M
Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.